245 related articles for article (PubMed ID: 9076462)
1. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G
Eur Urol; 1997; 31(2):178-81. PubMed ID: 9076462
[TBL] [Abstract][Full Text] [Related]
2. Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergoline.
Lissoni P; Vaghi M; Villa S; Bodraska A; Cerizza L; Tancini G; Gardani GS
Anticancer Res; 2003; 23(1B):733-6. PubMed ID: 12680176
[TBL] [Abstract][Full Text] [Related]
3. Cancer as the main aging factor for humans: the fundamental role of 5-methoxy-tryptamine in reversal of cancer-induced aging processes in metabolic and immune reactions by non-melatonin pineal hormones.
Lissoni P; Messina G; Rovelli F
Curr Aging Sci; 2012 Dec; 5(3):231-5. PubMed ID: 23451999
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
5. Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate.
Sasagawa I; Kubota Y; Nakada T; Suzuki H; Hirano J; Sugano O; Kato H; Imamura A; Mastushita K; Onmura Y; Saito M; Adachi M
Int Urol Nephrol; 1998; 30(6):745-53. PubMed ID: 10195870
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.
Di Silverio F; Sciarra A
J Urol; 2003 Nov; 170(5):1812-6. PubMed ID: 14532782
[TBL] [Abstract][Full Text] [Related]
7. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
[TBL] [Abstract][Full Text] [Related]
9. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
Abbou CC; Lucas C; Leblanc V
Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of long-acting gonadotropin-releasing hormone analogue in the treatment for metastatic prostate cancer].
Li NC; Song Y; Jiang HW; Ding Q; Gan WD; Guo HQ; Sun ZY; Hu ZQ; Ye ZQ; Wei Q; Na YQ
Zhonghua Wai Ke Za Zhi; 2008 Nov; 46(21):1653-7. PubMed ID: 19094763
[TBL] [Abstract][Full Text] [Related]
11. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
Dimopoulos MA; Kiamouris C; Gika D; Deliveliotis C; Giannopoulos A; Zervas A; Alamanis C; Constantinidis C; Koutsilieris M
Urology; 2004 Jan; 63(1):120-5. PubMed ID: 14751362
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
14. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.
Lissoni P; Paolorossi F; Tancini G; Ardizzoia A; Barni S; Brivio F; Maestroni GJ; Chilelli M
Br J Cancer; 1996 Nov; 74(9):1466-8. PubMed ID: 8912546
[TBL] [Abstract][Full Text] [Related]
16. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.
Lissoni P; Barni S; Meregalli S; Fossati V; Cazzaniga M; Esposti D; Tancini G
Br J Cancer; 1995 Apr; 71(4):854-6. PubMed ID: 7710954
[TBL] [Abstract][Full Text] [Related]
17. [Change of the LHRH analogue in progressive castration-refractory prostate cancer].
Heidenreich A; Porres D; Epplen R; van Erps T; Pfister D
Urologe A; 2012 Sep; 51(9):1282-7. PubMed ID: 22733398
[TBL] [Abstract][Full Text] [Related]
18. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin.
Lissoni P; Tancini G; Barni S; Paolorossi F; Ardizzoia A; Conti A; Maestroni G
Support Care Cancer; 1997 Mar; 5(2):126-9. PubMed ID: 9069612
[TBL] [Abstract][Full Text] [Related]
19. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.
Lissoni P
Pathol Biol (Paris); 2007; 55(3-4):201-4. PubMed ID: 17446010
[TBL] [Abstract][Full Text] [Related]
20. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
